Archive | Press Releases

RSS feed for this section

Daxor Corporation Appoints Kathryn A. Kornafel Vice President of Marketing and Commercial Development

NEW YORK , June 12, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Kathryn A. Kornafel as vice president of Marketing and Commercial Development. “Kathryn’s extensive marketing experience within the diagnostic, cardiovascular and point-of-care arenas position her to […]

Daxor Corporation Initiates Study with Virginia Commonwealth University to Measure Improvement of Survival Rates Following Burn Surgery As A Result of Optimized Blood Volume Assessment

NEW YORK – June 4, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the initiation of an investigator-initiated trial at Virginia Commonwealth University Medical Center that will incorporate the company’s patented BVA-100 diagnostic to assess blood volume loss during burn surgery. “Intravascular […]

DAXOR CORPORATION RETAINS CORE IR AS INVESTOR RELATIONS FIRM OF RECORD

NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces it has retained CORE IR as its Investor Relations firm of record. Core IR will provide comprehensive investor relations and shareholder communications services and assist the company in expanding […]

DAXOR CORPORATION TO PRESENT AT THE LD MICRO 8TH ANNUAL INVITATIONAL ON JUNE 4, 2018

NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, announced that Michael Feldschuh, Chief Executive Officer of Daxor, will be a featured presenter at the LD Micro Invitational Conference on Monday June 4, 2018 at 4:30 PM Pacific Time. The […]

A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use

New York, NY, April 19, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the publication of new research utilizing the BVA-100 blood volume analyzer that highlights significant, often unrecognized blood loss in cardiac surgery. The paper entitled “Measurement of Blood Loss in Cardiac Surgery: Still […]

Daxor to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House

New York, NY, April 4, 2018 Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces it will present at 3:00pm on Monday, April 9th at this year’s MicroCap Conference and will be available for meetings with investors on both April 9th and 10th. Michael Feldschuh, CEO of Daxor stated, […]

Daxor to Exhibit at the American Association of Heart Failure Nurses 2018 Advanced Heart Failure Symposium

New York, NY, March 22, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces it will exhibit for the first time at the American Association of Heart Failure Nurses Advanced Heart Failure Symposium, a medical education and medical technology exhibition held on March 23th and 24th in […]

New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session

New York, NY, March 14, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the presentation of new research highlighting the significant benefits to patient outcomes through individualization of care guided by blood volume analysis (BVA). The study by John E. Strobeck, MD, PhD and Wayne […]

Daxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting

New York, NY, March 9, 2018 – Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, exhibited at the 2018 Society for Critical Care Medicine Annual Meeting from February 25-28 in San Antonio, Texas where research was presented highlighting the positive clinical benefits of the use of Daxor’s BVA-100 blood […]

Daxor Corporation Announces Rise in Kit Sales, New Device Sale, and Filing of Form N-CSR for 2017

New York, NY, March 8, 2018 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2017. In reporting its annual results for its medical device division, Daxor cited a 25% rise in kit sales related […]